Individualized Treatments in Adults With Relapsed/Refractory Cancers

Status Recruiting

Clinical Trial Summary

A personalized cancer medicine approach would address therapy resistance, cancer metastasis, and limited options after standard of care is exhausted in advanced cancer participants. This approach may reduce the barriers to approved therapeutic assignment currently limited to a particular cancer type or patient demographic.

Clinical Trial Description

Treatment itself will not be given as part of this trial. The results of the drug sensitivity test (DST) and genomic screening will be used to inform treating physician about participant-specific drug sensitivity or resistance guiding best therapy choices. The physician will decide the most appropriate treatment for each case, with the option to add one or more personalized (assay-guided) drug(s) from the investigational platform. All participants will need to be consented separately for any subsequent investigational treatment if no standard treatment options are available. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06024603
Study type	Interventional
Source	Case Comprehensive Cancer Center
Contact	Jorge Manrique-Succar, MD
Phone	(954) 659-5000
Email	manriqj@ccf.org
Status	Recruiting
Phase	N/A
Start date	November 20, 2023
Completion date	November 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03336931` - PRecISion Medicine for Children With Cancer
Recruiting	`NCT05681195` - Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas	Phase 2
Completed	`NCT00530192` - Molecular Profiling Protocol (SCRI-CA-001)	Phase 0
Recruiting	`NCT05852717` - Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma	Phase 2
Recruiting	`NCT06229340` - Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations	Phase 2
Completed	`NCT00551850` - A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients	Phase 1
Recruiting	`NCT06104488` - A Study of Avutometinib for People With Solid Tumor Cancers	Phase 1
Terminated	`NCT04092179` - Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers	Phase 1/Phase 2
Recruiting	`NCT06184035` - A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer	Phase 1/Phase 2
Recruiting	`NCT05859074` - A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer	Phase 1
Recruiting	`NCT05864144` - A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT03187288` - Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS	Phase 1
Terminated	`NCT01320280` - BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer	Phase 2
Completed	`NCT03441100` - TCR-engineered T Cells in Solid Tumors: IMA202-101	Phase 1
Recruiting	`NCT05359445` - IMA401 TCER® in Recurrent and/or Refractory Solid Tumors	Phase 1
Recruiting	`NCT03686124` - ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors	Phase 1
Recruiting	`NCT04337580` - Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer	Phase 2
Active, not recruiting	`NCT04310345` - Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents	N/A
Recruiting	`NCT05669430` - A Study of GV20-0251 in Patients With Solid Tumor Malignancies	Phase 1
Not yet recruiting	`NCT06208657` - Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer	Phase 1/Phase 2